Bino Pathiparampil of IIFL, says that stock like Sun Pharma has been beating estimates for last eight quarters and the same performance is likely to continue in this quarter. Ranbaxy‘s business has been worsening over the last 2-3 quarters and one can‘t expect major improvement to happen in the base business.
first published: Apr 18, 2013 06:33 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.